Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mirati Therapeutics, Inc. (MRTX : NSDQ)
 
 • Company Description   
Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.

Number of Employees: 593

 
 • Price / Volume Information   
Yesterday's Closing Price: $37.01 Daily Weekly Monthly
20 Day Moving Average: 1,021,168 shares
Shares Outstanding: 58.19 (millions)
Market Capitalization: $2,153.50 (millions)
Beta: 1.02
52 Week High: $101.30
52 Week Low: $35.70
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.77% -20.89%
12 Week -9.18% -15.69%
Year To Date -18.32% -25.70%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3545 CRAY COURT
-
SAN DIEGO,CA 92121
USA
ph: 858-332-3410
fax: -
ir@mirati.com http://www.mirati.com
 
 • General Corporate Information   
Officers
David D. Meek - Chief Executive Officer
Faheem Hasnain - Chairman
Laurie D. Stelzer - Chief Financial Officer
Aaron Davis - Director
Craig Johnson - Director

Peer Information
Mirati Therapeutics, Inc. (CORR.)
Mirati Therapeutics, Inc. (RSPI)
Mirati Therapeutics, Inc. (CGXP)
Mirati Therapeutics, Inc. (BGEN)
Mirati Therapeutics, Inc. (GTBP)
Mirati Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60468T105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/02/23
Share - Related Items
Shares Outstanding: 58.19
Most Recent Split Date: 7.00 (0.02:1)
Beta: 1.02
Market Capitalization: $2,153.50 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-3.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-12.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.49
Price/Cash Flow: -
Price / Sales: 113.98
EPS Growth
vs. Year Ago Period: 6.47%
vs. Previous Quarter: 9.40%
Sales Growth
vs. Year Ago Period: 910.86%
vs. Previous Quarter: 667.34%
ROE
03/31/23 - -71.90
12/31/22 - -66.05
09/30/22 - -60.40
ROA
03/31/23 - -61.18
12/31/22 - -56.92
09/30/22 - -52.78
Current Ratio
03/31/23 - 7.54
12/31/22 - 6.95
09/30/22 - 9.65
Quick Ratio
03/31/23 - 7.51
12/31/22 - 6.94
09/30/22 - 9.65
Operating Margin
03/31/23 - -3,901.06
12/31/22 - -5,957.44
09/30/22 - -6,253.81
Net Margin
03/31/23 - -3,901.06
12/31/22 - -5,957.44
09/30/22 - -6,253.81
Pre-Tax Margin
03/31/23 - -3,898.38
12/31/22 - -5,953.35
09/30/22 - -6,251.66
Book Value
03/31/23 - 14.82
12/31/22 - 17.31
09/30/22 - 20.30
Inventory Turnover
03/31/23 - 0.83
12/31/22 - 0.79
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©